Drug merger not expected to have big impact on N.J.

November 24, 2015

James Hughes, dean of the Bloustein School of Planning & Public Policy at Rutgers University, also said he did not see much duplication to be cut.

“Allergan has a sales staff that deals with their specific products, and Pfizer has its staff for different products. So I would think that staff is going to stay intact,” Hughes said. “It shouldn’t have much of an impact one way or the other on New Jersey.”

Wall Street Journal, November 23

Recent Posts

NJSPL: Detecting Change in NJ Historical Water Bodies Using ArcGIS Pro

As we finish creating digital representations, or features, of historical water bodies for our project to create a dataset of historical water bodies in New Jersey, we begin exploring how these water bodies have changed over time. In GIS, the process of quantifying...